相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors
Richard Riedel et al.
EUROPEAN JOURNAL OF CANCER (2023)
Design, synthesis, and biological evaluation of 2, 4-dichlorophenoxyacetamide chalcone hybrids as potential c-Met kinase inhibitors
Heena Bhojwani et al.
MEDICINAL CHEMISTRY RESEARCH (2023)
Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Roles of MET in human cancer
Xin Yang et al.
CLINICA CHIMICA ACTA (2022)
Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition
Tahereh Damghani et al.
MOLECULAR DIVERSITY (2022)
Synthesis of triazolotriazine derivatives as c-Met inhibitors
Yuting Guo et al.
MOLECULAR DIVERSITY (2021)
Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors
Daowei Huang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design, synthesis and biological evaluation of novel 4-(pyrrolo[2,3-d]pyrimidine-4-yloxy)benzamide derivatives as potential antitumor agents
Jianqing Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors
Qing Tang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
MET inhibitors in cancer: pitfalls and challenges
Helena Oliveres et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
MET targeting: time for a rematch
Jonas P. Koch et al.
ONCOGENE (2020)
Crizotinib in ROS1 and MET Deregulated NSCLC-Letter
Marcel Wiesweg et al.
CLINICAL CANCER RESEARCH (2020)
Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors
Zhen Wang et al.
BIOORGANIC CHEMISTRY (2020)
Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo [1,5-a] pyrimidine derivatives as potential c-Met inhibitors
Guolin Luo et al.
BIOORGANIC CHEMISTRY (2020)
C-MET inhibitors for advanced non-small cell lung cancer
Giulia Pasquini et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2
Wei Shi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Cabozantinib for the treatment of kidney cancer
Ahmed Abdelaziz et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Development of efficient docking strategies and structure-activity relationship study of the c-Met type II inhibitors
Ming-Jing Li et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2017)
Fluorination methods in drug discovery
Damian E. Yerien et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2016)
Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib
Maocai Yan et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2016)
Discovery of novel type II c-Met inhibitors based on BMS-777607
Wei Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
The Novel VEGF Receptor/MET-Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
Hidenori Fujita et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Progress in cancer therapy targeting c-Met signaling pathway
Kyung Hee Jung et al.
ARCHIVES OF PHARMACAL RESEARCH (2012)
Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors
Wenting Tai et al.
JOURNAL OF MOLECULAR MODELING (2012)
An overview of the c-MET signaling pathway
Shawna Leslie Organ et al.
Therapeutic Advances in Medical Oncology (2011)
分享论文
